Are there protective treatments for cognitive decline in MS?

Journal of the Neurological Sciences
Maria Pia AmatoValentina Zipoli

Abstract

Despite its frequency and high functional impact, very little is known about effective strategies for managing cognitive impairment in multiple sclerosis (MS). Disease-modifying drugs, such as beta-interferons and glatiramer acetate, may prevent or reduce the progression of cognitive dysfunction by containing the development of new cerebral lesions. To date, clinical trials have provided inconsistent results, with neuropsychological effects documented only in one trial. Moreover, pilot studies have tested symptomatic therapies for fatigue, a frequent symptom in MS, which may share a common physiopathological substrate with cognitive dysfunction. Small trials with amantadine, pemoline, 4-aminopyridine and 3-4 aminopyridine have provided mainly negative results. Acetylcholinesterase inhibitors (AChEI) used to treat Alzheimer's disease (AD)-such as donepezil, rivastigmine, and galantamine-have recently been tested in other cognitive disorders, including MS. The majority of pilot trials with AchEI in MS have provided promising results, and the donepezil study recently published by Krupp et al. represents a major development in this field. As for non-pharmacological interventions based on cognitive rehabilitation, few studies have u...Continue Reading

References

Jun 1, 1989·Archives of Neurology·R A Cohen, M Fisher
Apr 6, 1999·Archives of Neurology·A WeinsteinS I Schwid
Jan 11, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·N B LincolnE D Playford
Jan 18, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·K W RammohanH N Nagaraja
Jan 23, 2002·European Neurology·Yoram Barak, Anat Achiron
Jan 25, 2005·Lancet Neurology·Maria Pia Amato

❮ Previous
Next ❯

Citations

May 16, 2007·Journal of Neurology·Alexander WinkelmannUwe K Zettl
Aug 22, 2012·Journal of Clinical and Experimental Neuropsychology·Brian M Sandroff, Robert W Motl
Mar 13, 2010·International Review of Psychiatry·Epameinondas LyrosPanagiotis Papathanasopoulos
Jun 5, 2012·Revue neurologique·C BensaUNKNOWN Multiple Sclerosis Think Tank (Groupe de reflexion sur la sclerose en plaques GRESEP)
Aug 8, 2008·Journal of Neuroimmunology·Talma BrennerItzhak Wirguin
Apr 1, 2008·Archives of Physical Medicine and Rehabilitation·Amanda R O'BrienJohn Deluca
May 1, 2007·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Cinthia M MazzantiMaria Rosa C Schetinger
Nov 21, 2008·Journal of Neuroscience Research·Akvile NorkuteMarkus Kipp
Jan 1, 2014·Multiple Sclerosis and Related Disorders·Brian M SandroffRobert W Motl
Sep 2, 2016·Acta Neurologica Scandinavica·M MückschelT Ziemssen
Oct 25, 2016·Journal of the Neurological Sciences·Manuel E HernandezRobert W Motl
Aug 24, 2010·Arquivos de neuro-psiquiatria·Maria Lúcia Brito Ferreira
Sep 23, 2008·Multiple Sclerosis : Clinical and Laboratory Research·F Patti
Jun 21, 2011·Multiple Sclerosis : Clinical and Laboratory Research·Robert W MotlRalph H B Benedict
Jun 25, 2008·Multiple Sclerosis : Clinical and Laboratory Research·B DuqueP Villoslada
Jan 1, 2009·Therapeutic Advances in Neurological Disorders·Ida S HaussleiterGeorg Juckel
Dec 18, 2013·The Cochrane Database of Systematic Reviews·Dian HeHongyu Zhou
Jun 27, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·D BrunoM Roca
Nov 1, 2008·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Vahid ShaygannejadNaser Zakizade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.